1-3 of 3
MB van 't Veer
Close
Sort by
Journal Articles

Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial

Christian H Geisler, MD, PhD, Mars MB van 't Veer, MD, PhD, Wim van Putten, MSc, Jesper Jurlander, MD.PHD, Jan Walewski, MD, PhD, Geir Tjonnfjord, MD, PHD, Maija Itälä-Remes, MD, PHD, Eva Kimby, M.D., Ph.D., Tomas Kozak, MD, PhD, Aaron Polliack, MD, Shulamiet Wittebol, MD, Fokje Spoelstra, PhD, Marinus H.J. Van Oers, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 290.
https://doi.org/10.1182/blood.V118.21.290.290
Published: 2011
Journal Articles

Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation

EJ Gerritsen, MJ Van Tol, MB Van 't Veer, JM Wels, IM Khouw, CR Touw, CM Jol-Van Der Zijde, J Hermans, HC Rumke, J Radl
Journal: Blood
Blood (1994) 84 (12): 4374–4382.
https://doi.org/10.1182/blood.V84.12.4374.bloodjournal84124374
Published: 1994
Journal Articles

Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen

PJ van Genderen, T Vink, JJ Michiels, MB van 't Veer, JJ Sixma, HH van Vliet
Journal: Blood
Blood (1994) 84 (10): 3378–3384.
https://doi.org/10.1182/blood.V84.10.3378.3378
Published: 1994